Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$136.14 USD

136.14
303,461

+0.90 (0.67%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $136.09 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.

Masimo (MASI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 4.82% and 1.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.

ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 15.38% and 2.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Masimo (MASI) Q1 Earnings Expected to Decline

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Masimo and Black Knight have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Masimo and Black Knight have been highlighted as Zacks Bull and Bear of the Day.

Bryan Hayes headshot

Bull of the Day: Masimo Corp. (MASI)

by Bryan Hayes

This stock has benefitted from a resurgence in the health care sector.

3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Masimo's (MASI) New FDA Approval to Improve Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.

Intuitive Surgical (ISRG) Gains Following Q1 Earnings Beat

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.

3 Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Is Masimo (MASI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Masimo (MASI) and Ocuphire Pharma, Inc. (OCUP) have performed compared to their sector so far this year.

QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Intuitive Surgical (ISRG) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Here's Why You Should Hold Teladoc Health (TDOC) Stock Now

by Zacks Equity Research

Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.

Masimo (MASI) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Masimo's (MASI) slew of product launches.

BD's (BDX) New Launch to Result in Optimal IV Placement

by Zacks Equity Research

BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.

What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?

by Zacks Equity Research

Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.

Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

PacBio's (PACB) New Offering to Enable High-Throughput Workflows

by Zacks Equity Research

PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.

Baxter's (BAX) New Premix Drug Now Available in the U.S.

by Zacks Equity Research

Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.